This company listing is no longer active
Resumen de acción BDRX
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 1 riesgos adicionales
Competidores de Biodexa Pharmaceuticals Plc
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.037 |
| 52 Week High | UK£3.18 |
| 52 Week Low | UK£0.038 |
| Beta | 1.13 |
| 1 Month Change | -76.56% |
| 3 Month Change | -90.38% |
| 1 Year Change | -98.47% |
| 3 Year Change | -99.59% |
| 5 Year Change | -99.97% |
| Change since IPO | -100.00% |
Noticias y actualizaciones recientes
Rentabilidad de los accionistas
| BDRX | GB Biotechs | Mercado GB | |
|---|---|---|---|
| 7D | -16.7% | 2.2% | 2.8% |
| 1Y | -98.5% | -27.7% | 1.1% |
Rentabilidad vs. Industria: BDRX underperformed the UK Biotechs industry which returned -15.3% over the past year.
Rentabilidad vs. Mercado: BDRX underperformed the UK Market which returned -1% over the past year.
Volatilidad de los precios
| BDRX volatility | |
|---|---|
| BDRX Average Weekly Movement | 19.9% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Precio estable de las acciones: BDRX's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: BDRX's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of UK stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2000 | 20 | Stephen Stamp | www.biodexapharma.com |
Resumen de fundamentos de Biodexa Pharmaceuticals Plc
| Estadísticas fundamentales de BDRX | |
|---|---|
| Capitalización bursátil | UK£3.55m |
| Beneficios(TTM) | -UK£5.37m |
| Ingresos (TTM) | UK£645.00k |
5.5x
Ratio precio-ventas (PS)-0.7x
Ratio precio-beneficio (PE)¿Está BDRX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de BDRX | |
|---|---|
| Ingresos | UK£645.00k |
| Coste de los ingresos | UK£4.65m |
| Beneficio bruto | -UK£4.01m |
| Otros gastos | UK£1.36m |
| Beneficios | -UK£5.37m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.057 |
| Margen bruto | -621.55% |
| Margen de beneficio neto | -832.09% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado BDRX a largo plazo?
Ver rendimiento histórico y comparativa